This is a demo store. No orders will be fulfilled.

Life Sciences

Frost & Sullivan's expertise in Life Sciences research and consulting includes work in diversified strategic and operational areas

The life sciences industry is undergoing rapid change, dynamic discoveries and pressures driving business decisions and corporate growth. Business models are being forced to evolve as healthcare continues to shift from a treatment focus to points of wellness, prediction, personalization, and prevention.

Recognizing the interdependence of the payer, provider and pharmaceutical value chains, companies are re-inventing strategies in multitude ways: increased outsourcing, co-development and patient engagement are the new norms.

The Frost & Sullivan Global Life Sciences Program helps you better understand stakeholder dynamics as the healthcare system transitions from acute care into integrated care. Our research and insights help you make informed strategic decisions around how best to navigate this complex market.

We can support needs from syndicated research to projects ranging from proprietary strategic engagements and market research, marketing solutions, and whitepapers, all leveraging the global reach of our firm to propel your business forward.

We believe a structured partnership that provides you transformational insights through online content as well as deeper interaction with our senior analyst team will help ensure greater relevancy of insights provided for your organization.

  1. 31 Jan 2020  |  North America  |  Market Research

    Predictions for the Global Life Sciences Industry, 2020

    COVID-19 Pandemic will Drive New Digital-tech Adoption in Drug Discovery and Testing Services, and Federal Funding will Encourage Stronger Product Pipelines

    The growth trajectory of the global life sciences industry has benefited from a combination of novel technologies such as CRISPR-Cas9, microbiome and single-cell, relaxation of entry barriers in markets like China, and better-defined regulatory frameworks around next-generation therapies and companion diagnostics. A common denominator of growth a...

    $1,500.00
  2. 11 Apr 2019  |  North America  |  Market Research

    Pharma Clinical Trial Digitization—Companies to Action, 2019

    Collision of Healthcare with Life Sciences IT Systems will Continue to Transform the Clinical Trials Market

    Despite the term patient centricity gaining currency in the industry, there is a degree of variability in a companies’ approach and strategic priorities. Frost & Sullivan sees digitization playing a critical role in transforming the clinical trial model from traditional, high-cost, and difficult-to-access centralized settings to more patient-cent...

    $1,500.00
  3. 20 Mar 2019  |  North America  |  Market Research

    2019 Predictions of the Global Life Sciences Industry

    As Novel Technologies Find Traction, Industry Focus Will Shift Towards Successful Monetization to Deliver Value-based Care

    he global life science industry is in a state of flux. While the recent years have seen the advent of multiple novel technologies, such as in-vitro diagnostics (IVD), CRISPR-Cas9, virtual clinical trials, and liquid biopsy, the industry stands at a crossroad with challenges in scaling-up and commercializing such technologies. In addition, companies...

    $1,500.00
  4. 30 Oct 2018  |  Africa  |  Market Research

    Healthcare Regulatory Environment in Kenya, Tanzania, and Ethiopia, 2018

    Unlocking Investment Potential and Improving Healthcare Delivery and Access through Policy Advancement

    The East African region boasts of a number of emerging leaders within Sub-Saharan Africa in terms of overall development and growth. On one hand, the region has one of the highest burdens of disease in the world, such as HIV, malaria, and tuberculosis. On the other hand, there has been a growing trend of non-communicable diseases, such as cancers a...

    $1,500.00